{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:35:16Z","timestamp":1792521316930,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Cognitive symptoms negatively impact people with narcolepsy type 1 (NT1). While the effects of orexin receptor 2 (OX2R) agonists have been explored on diagnostic features of the disorder (excessive daytime sleepiness and cataplexy), effects on cognitive symptoms are not characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore the effects of oveporexton, an oral OX2R-selective agonist, on cognition in people with NT1.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This is a secondary analysis of the TAK-861-2001 phase 2, 8-week, parallel-group, double-blind, placebo-controlled randomized clinical trial, conducted from January 2023 to December 2023, with a 4-week follow-up period. TAK-861-2001 was a multicenter study conducted in clinical settings. Eligible participants were 18 to 70 years of age, with an\n International Classification of Sleep Disorders, Third Edition<\/jats:italic>\n diagnosis of NT1. Data analysis was performed from July 2024 to July 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized 1:1:1:1:1 to twice-daily oral oveporexton or matching placebo, dosed 3 hours apart, in dose groups of 0.5\/0.5 mg, 2\/2 mg, 2\/5 mg, 7 mg\/placebo, or placebo\/placebo, for 8 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Cognitive symptoms were assessed using the Psychomotor Vigilance Task (PVT) for attention, the Continuous Paired Associate Learning (CPAL) test for memory, and the One Back (ONB) test and International Digit Symbol Substitution Test\u2013symbols (IDSST-s) for executive function.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 161 eligible individuals screened, 48 did not meet study inclusion criteria, 1 withdrew, and 112 were included in the study. Of 112 participants, mean (SD) age was 34.0 (11.5) years, and 58 participants (51.8%) were female. A total of 112 participants were randomized and received 1 or more doses of oveporexton (0.5\/0.5 mg, n\u2009=\u200923; 2\/2 mg, n\u2009=\u200921; 2\/5 mg, n\u2009=\u200923; 7 mg, n\u2009=\u200923) or placebo (n\u2009=\u200922). Oveporexton improved attention, memory, and executive function over 8 weeks. Least-squares (LS) mean placebo-adjusted changes from baseline were \u221210.77 (95% CI, \u221216.74 to \u22124.79), \u22129.45 (95% CI, \u221215.66 to \u22123.24), \u22128.60 (95% CI, \u221214.84 to \u22122.36), and \u22128.69 (95% CI, \u221214.90 to \u22122.47) PVT lapses with 0.5\/0.5 mg, 2\/2 mg, 2\/5 mg, and 7 mg\/placebo doses, respectively. LS mean placebo-adjusted changes were \u221222.52 (95% CI, \u221234.95 to \u221210.10), \u221216.92 (95% CI, \u221230.12 to \u22123.71), \u221215.51 (95% CI, \u221228.82 to \u22122.21), and \u221217.59 (95% CI, \u221230.50 to \u22124.68) for CPAL errors; \u22120.05 (95% CI, \u22120.10 to \u22120.01), \u22120.07 (95% CI, \u22120.12 to \u22120.02), \u22120.07 (95% CI, \u22120.12 to \u22120.02), and \u22120.05 (95% CI, \u22120.10 to 0.00) units for ONB log10-transformed performance speed; and 4.72 (95% CI, \u22121.38 to 10.83), 7.33 (95% CI, 1.06-13.61), 7.85 (95% CI, 1.75-13.95), and 11.82 (95% CI, 5.75-17.89) for IDSST-s correct responses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of the TAK-861-2001 randomized clinial trial, the OX2R agonist oveporexton improved NT1-associated cognitive symptoms in adults.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05687903<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.4825","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:01:06Z","timestamp":1765209666000},"page":"145","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Oveporexton, an Orexin Receptor 2\u2013Selective Agonist, on Cognition in Narcolepsy Type 1"],"prefix":"10.1001","volume":"83","author":[{"given":"Gert Jan","family":"Lammers","sequence":"first","affiliation":[{"name":"Stichting Epilepsie Instellingen Nederland, Sleep-Wake Centre, Heemstede, the Netherlands"},{"name":"Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Plazzi","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"},{"name":"Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mignot","sequence":"additional","affiliation":[{"name":"Stanford Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pizza","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"},{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[{"name":"Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, CHU, Montpellier, France"},{"name":"National Reference Network for Narcolepsy, Montpellier, France"},{"name":"Institute for Neurosciences of Montpellier (INM), INSERM, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Barateau","sequence":"additional","affiliation":[{"name":"Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, CHU, Montpellier, France"},{"name":"National Reference Network for Narcolepsy, Montpellier, France"},{"name":"Institute for Neurosciences of Montpellier (INM), INSERM, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maruff","sequence":"additional","affiliation":[{"name":"Cogstate, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Scammell","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Latzman","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Naylor","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Olsson","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Stukalin","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Volfson","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahe","family":"Khachadourian","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Harel","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"27","key":"noi250083r1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy.","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med"},{"key":"noi250083r3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/issn.0300-5186","article-title":"Hypocretin\/orexin receptor pharmacology and sleep phases.","volume":"45","author":"Sun","year":"2021","journal-title":"Front Neurol Neurosci"},{"key":"noi250083r4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fendo.2013.00057","article-title":"Differential roles of orexin receptors in the regulation of sleep\/wakefulness.","volume":"4","author":"Mieda","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"noi250083r5","doi-asserted-by":"publisher","first-page":"8473","DOI":"10.1038\/s41598-022-12601-x","article-title":"Orexin 2 receptor (OX2R) protein distribution measured by autoradiography using radiolabeled OX2R-selective antagonist EMPA in rodent brain and peripheral tissues.","volume":"12","author":"Mitsukawa","year":"2022","journal-title":"Sci Rep"},{"issue":"19","key":"noi250083r6","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa2405847","article-title":"Oveporexton, an oral orexin receptor 2-selective agonist, in narcolepsy type 1.","volume":"392","author":"Dauvilliers","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"noi250083r7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2301940","article-title":"Oral orexin receptor 2 agonist in narcolepsy type 1.","volume":"389","author":"Dauvilliers","year":"2023","journal-title":"N Engl J Med"},{"issue":"35","key":"noi250083r8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.","volume":"119","author":"Evans","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"noi250083r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101510","article-title":"Cognitive dysfunction in central disorders of hypersomnolence: a systematic review.","volume":"59","author":"Filardi","year":"2021","journal-title":"Sleep Med Rev"},{"issue":"3","key":"noi250083r10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5664\/jcsm.6494","article-title":"Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy.","volume":"13","author":"Maski","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"noi250083r11","doi-asserted-by":"publisher","first-page":"A351","DOI":"10.1093\/sleep\/zsaf090.0811","article-title":"Characterizing patient-reported cognitive symptoms and their impact on daily life in narcolepsy type 1 (0811).","volume":"48","author":"Maski","year":"2025","journal-title":"Sleep (Basel)"},{"issue":"1","key":"noi250083r13","doi-asserted-by":"publisher","DOI":"10.1093\/sleepadvances\/zpae043","article-title":"The nature and magnitude of cognitive impairment in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia: a meta-analysis.","volume":"5","author":"Harel","year":"2024","journal-title":"Sleep Adv"},{"issue":"2","key":"noi250083r14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/brainsci12020150","article-title":"Neurobiology of the orexin system and its potential role in the regulation of hedonic tone.","volume":"12","author":"Katzman","year":"2022","journal-title":"Brain Sci"},{"issue":"9","key":"noi250083r15","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae150","article-title":"Impaired cognition in narcolepsy: clinical and neurobiological perspectives.","volume":"47","author":"Cano","year":"2024","journal-title":"Sleep"},{"issue":"7","key":"noi250083r16","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab114","article-title":"Standardization of psychomotor vigilance testing methods and reporting.","volume":"44","author":"Basner","year":"2021","journal-title":"Sleep"},{"issue":"1","key":"noi250083r17","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa121","article-title":"Response speed measurements on the psychomotor vigilance test: how precise is precise enough?","volume":"44","author":"Basner","year":"2021","journal-title":"Sleep"},{"issue":"6","key":"noi250083r18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1037\/a0024237","article-title":"Examining the nature of impairment in visual paired associate learning in amnestic mild cognitive impairment.","volume":"25","author":"Harel","year":"2011","journal-title":"Neuropsychology"},{"issue":"2","key":"noi250083r19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/arclin\/acp010","article-title":"Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex.","volume":"24","author":"Maruff","year":"2009","journal-title":"Arch Clin Neuropsychol"},{"issue":"10","key":"noi250083r20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1080\/13803395.2023.2179977","article-title":"Validation of a digit symbol substitution test for use in supervised and unsupervised assessment in mild Alzheimer\u2019s disease.","volume":"44","author":"Williamson","year":"2022","journal-title":"J Clin Exp Neuropsychol"},{"issue":"20","key":"noi250083r21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.3639","article-title":"Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?","volume":"28","author":"Liu","year":"2009","journal-title":"Stat Med"},{"key":"noi250083r23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-024-01141-9","article-title":"Narcolepsy: beyond the classic pentad.","volume":"39","author":"Morse","year":"2025","journal-title":"CNS Drugs"},{"issue":"5","key":"noi250083r24","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13593","article-title":"Is memory impaired in narcolepsy type 1?","volume":"31","author":"Medrano-Mart\u00ednez","year":"2022","journal-title":"J Sleep Res"},{"issue":"2","key":"noi250083r25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/15402002.2023.2217971","article-title":"The burden of narcolepsy in adults: a population sampling study using personal media.","volume":"22","author":"Quaedackers","year":"2024","journal-title":"Behav Sleep Med"},{"issue":"2","key":"noi250083r26","first-page":"187","article-title":"Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART).","volume":"29","author":"Fronczek","year":"2006","journal-title":"Sleep"},{"key":"noi250083r27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.npep.2019.03.004","article-title":"Serotonergic neurons in the dorsal raphe nucleus mediate the arousal-promoting effect of orexin during isoflurane anesthesia in male rats.","volume":"75","author":"Yang","year":"2019","journal-title":"Neuropeptides"},{"issue":"4","key":"noi250083r28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.neuron.2018.01.008","article-title":"Neuromodulation of attention.","volume":"97","author":"Thiele","year":"2018","journal-title":"Neuron"},{"key":"noi250083r29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.neuro.051508.135535","article-title":"The neuropsychopharmacology of fronto-executive function: monoaminergic modulation.","volume":"32","author":"Robbins","year":"2009","journal-title":"Annu Rev Neurosci"},{"issue":"12","key":"noi250083r30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/cercor\/12.12.1254","article-title":"The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions.","volume":"12","author":"Passetti","year":"2002","journal-title":"Cereb Cortex"},{"issue":"4","key":"noi250083r31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/JCP.0000000000001562","article-title":"Acute cognitive effects of the dual orexin receptor antagonist lemborexant compared with suvorexant and zolpidem in recreational sedative users.","volume":"42","author":"Landry","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"noi250083r32","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2022.1029554","article-title":"Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: a comprehensive dose-response meta-analysis.","volume":"16","author":"Zhou","year":"2023","journal-title":"Front Hum Neurosci"},{"issue":"5","key":"noi250083r33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.","volume":"16","author":"Murphy","year":"2020","journal-title":"J Clin Sleep Med"},{"key":"noi250083r2","volume-title":"International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine","year":"2014","edition":"3rd ed"},{"key":"noi250083r22","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"},{"key":"noi250083r12","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (CDER). Narcolepsy summary report: the voice of the patient. Accessed October 6, 2025. https:\/\/www.fda.gov\/media\/88736\/download"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2842314\/jamaneurology_lammers_2025_oi_250083_1770244433.76546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:00:25Z","timestamp":1770652825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2842314"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.4825","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}